Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion announced that its compensation committee granted stock options to one new employee on December 2, 2024. The grant includes options to purchase 30,000 shares of common stock, which will vest quarterly over four years at a rate of 1/16. The grant was made under Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023, and serves as an inducement for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Biomea Fusion ha annunciato che il suo comitato per le retribuzioni ha concesso opzioni su azioni a un nuovo dipendente il 2 dicembre 2024. La concessione include opzioni per l'acquisto di 30.000 azioni di azioni ordinarie, che matureranno trimestralmente per quattro anni con un tasso di 1/16. La concessione è stata effettuata nell'ambito del 2023 Inducement Equity Plan di Biomea, adottato il 17 novembre 2023, e funge da incentivo per l'impiego in conformità con la regola Nasdaq Listing Rule 5635(c)(4).
Biomea Fusion anunció que su comité de compensación otorgó opciones sobre acciones a un nuevo empleado el 2 de diciembre de 2024. La concesión incluye opciones para comprar 30,000 acciones de acciones ordinarias, que se adquirirán trimestralmente durante cuatro años a una tasa de 1/16. La concesión se realizó bajo el 2023 Inducement Equity Plan de Biomea, adoptado el 17 de noviembre de 2023, y sirve como incentivo para el empleo de acuerdo con la regla de listado Nasdaq 5635(c)(4).
Biomea Fusion은 보상 위원회가 2024년 12월 2일에 새로운 직원에게 주식 옵션을 부여했다고 발표했습니다. 이 부여에는 30,000주의 보통 주식을 구매할 수 있는 옵션이 포함되어 있으며, 4년에 걸쳐 분기마다 1/16의 비율로 취득됩니다. 이 부여는 2023년 11월 17일에 채택된 Biomea의 2023 Inducement Equity Plan에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 따른 고용 유인을 제공합니다.
Biomea Fusion a annoncé que son comité de rémunération a accordé des options d'achat d'actions à un nouvel employé le 2 décembre 2024. La concession comprend des options pour acheter 30 000 actions ordinaires, qui seront acquises trimestriellement sur quatre ans à un taux de 1/16. La concession a été faite dans le cadre du 2023 Inducement Equity Plan de Biomea, adopté le 17 novembre 2023, et sert d'incitation à l'emploi conformément à la règle de cotation Nasdaq 5635(c)(4).
Biomea Fusion gab bekannt, dass sein Vergütungsausschuss am 2. Dezember 2024 Aktienoptionen an einen neuen Mitarbeiter vergeben hat. Die Gewährung umfasst Optionen zum Kauf von 30.000 Aktien gewöhnlicher Aktien, die vierteljährlich über vier Jahre mit einer Rate von 1/16 fällig werden. Die Gewährung erfolgte im Rahmen des 2023 Inducement Equity Plan von Biomea, der am 17. November 2023 angenommen wurde, und dient als Anreiz für die Beschäftigung gemäß der Nasdaq Listing Rule 5635(c)(4).
- None.
- None.
REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that on December 2, 2024, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase an aggregate of 30,000 shares of the Company’s common stock. The shares underlying the employee’s stock options will vest 1/16 on a quarterly basis over four years, subject to the employee’s continued employment with the Company on such vesting dates. The above-described award was made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
The above-described award was granted as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and was granted pursuant to the terms of the Plan. The Plan was adopted by Biomea’s board of directors on November 17, 2023.
About Biomea Fusion
Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Investor & Media Relations
Ramses Erdtmann
re@biomeafusion.com
FAQ
How many shares were granted in Biomea Fusion's (BMEA) December 2024 inducement grant?
What is the vesting schedule for Biomea Fusion's (BMEA) December 2024 stock option grant?
When was Biomea Fusion's (BMEA) 2023 Inducement Equity Plan adopted?
